Atish Majumdar
Vendite & Marketing presso MANKIND PHARMA LIMITED
Profilo
Atish Majumdar is currently the Director at Actimed Therapeutics Ltd.
and the President-Sales & Marketing at Mankind Pharma Ltd.
He completed his undergraduate degree from the University of Calcutta.
Posizioni attive di Atish Majumdar
| Società | Posizione | Inizio |
|---|---|---|
| MANKIND PHARMA LIMITED | Vendite & Marketing | 09/11/2019 |
Actimed Therapeutics Ltd.
 Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Direttore/Membro del Consiglio | 04/01/2023 |
Formazione di Atish Majumdar
| University of Calcutta | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MANKIND PHARMA LIMITED | Health Technology |
| Aziende private | 1 |
|---|---|
Actimed Therapeutics Ltd.
Actimed Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Actimed Therapeutics Ltd. is a British clinical stage specialty pharmaceutical company that focuses on bringing innovation to the treatment of muscle wasting disorders. Actimed is based in Ascot, UK. Actimed's lead product, ACM-001 (S-pindolol), targets multiple biological pathways that drive cachexia and has generated promising proof of concept data in a phase II clinical trial in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The company is currently preparing for further clinical studies of cachexia in these two cancer types. The company was founded in 2017 by Stefan D. Anker and Andrew Justin Stewart Coats, two world-leading physicians in muscle wasting research, together with Yann Colardelle, a professional in communications and medical education. | Commercial Services |
- Borsa valori
- Insiders
- Atish Majumdar
